Back to Browse Journals » Biosimilars » Volume 1

Biosimilars: an overview

Authors Bhupinder Singh Sekhon, Vikrant Saluja

Published Date March 2011 Volume 2011:1 Pages 1—11

DOI http://dx.doi.org/10.2147/BS.S16120

Published 15 March 2011

Bhupinder Singh Sekhon, Vikrant Saluja
Institute of Pharmacy, PCTE Group of Institutes, Near Baddowal Cantt. (Ludhiana), India

Abstract: “Biologics”, considered one of the fastest growing sectors of the pharmaceutical industry, has introduced many new treatments to life-threatening and rare illnesses. The first generation of biopharmaceutical products manufactured using recombinant technologies was launched in the 1980s, and they are now on the way to patent expiration. As a result, research-based and generic pharmaceutical companies alike are pursuing the opportunity to develop “generic” substitutes for original biologics, herein referred to as biosimilars. However, the process of introducing a biosimilar to an innovator product is far more complex than the relatively straightforward process of introducing a generic equivalent to an innovator product based on a new chemical entity. Biologics are produced by cells in culture or whole organisms, which are inherently more variable than chemical synthesis methods. Therefore, unlike generic pharmaceuticals, it is impossible to generate the same or identical copy of an innovator product. In this way, biosimilars are “similar but not the same” or in other words biosimilars are “the twin but not the clone” to the original biologic innovator product. Therefore the field of biosimilars presents several important challenges, including i) verification of the similarity, ii) the interchangeability of biosimilars and innovator products, iii) the possible need for unique naming to differentiate the various biopharmaceutical products, iv) regulatory framework, v) commercial opportunities as well as guidelines to assist manufacturers in product development, vi) intellectual property rights, and vii) public safety.
Keywords: biosimilars, biologics, innovator product, pharmacovigilance, regulatory

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other articles by this author:

Food nanotechnology – an overview

Bhupinder S Sekhon

Nanotechnology, Science and Applications 2010, 3:1-15

Published Date: 4 May 2010

Nanotechnology in agri-food production: an overview

Sekhon BS

Nanotechnology, Science and Applications 2014, 7:31-53

Published Date: 20 May 2014

Matrix metalloproteinases – an overview

Bhupinder Singh Sekhon

Research and Reports in Biology 2010, 1:1-20

Published Date: 15 September 2010

Readers of this article also read:

Epigenomics in cancer management

Fabricio F Costa

Cancer Management and Research 2010, 2:255-265

Published Date: 27 October 2010

Amino acid-responsive Crohn's disease: a case study

Alvin Stein, Marty Hinz, Thomas Uncini

Clinical and Experimental Gastroenterology 2010, 3:171-177

Published Date: 6 December 2010

Biosimilar medicines and cost-effectiveness

Steven Simoens

ClinicoEconomics and Outcomes Research 2011, 3:29-36

Published Date: 10 February 2011

Scientific factors for assessing biosimilarity and drug interchangeability of follow-on biologics

Chow SC, Endrenyi L, Lachenbruch PA, Yang LY, Chi E

Biosimilars 2011, 1:13-26

Published Date: 16 June 2011

A European perspective on the market accessibility of biosimilars

Declerck PJ, Simoens S

Biosimilars 2012, 2:33-40

Published Date: 16 November 2012

Similar biotherapeutic products in Latin America. Regulation and opportunities for patients with autoimmune diseases

Desanvicente-Celis Z, Caro-Moreno J, Enciso-Zuluaga M, Anaya JM

Biosimilars 2013, 3:1-17

Published Date: 4 January 2013

Rituximab and biosimilars – equivalence and reciprocity

Qureshi ZP, Magwood JS, Singh S, Bennett CL

Biosimilars 2013, 3:19-25

Published Date: 14 June 2013